Stoke Therapeutics (STOK) Enterprise Value (2022 - 2025)
Stoke Therapeutics (STOK) has 4 years of Enterprise Value data on record, last reported at -$248.3 million in Q3 2025.
- For Q3 2025, Enterprise Value fell 65.44% year-over-year to -$248.3 million; the TTM value through Sep 2025 reached -$248.3 million, down 65.44%, while the annual FY2024 figure was -$216.9 million, 7.7% down from the prior year.
- Enterprise Value reached -$248.3 million in Q3 2025 per STOK's latest filing, roughly flat from -$247.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$150.1 million in Q3 2024 and bottomed at -$357.3 million in Q1 2025.
- Average Enterprise Value over 4 years is -$236.3 million, with a median of -$231.4 million recorded in 2023.
- Peak YoY movement for Enterprise Value: skyrocketed 30.1% in 2024, then crashed 100.09% in 2025.
- A 4-year view of Enterprise Value shows it stood at -$229.6 million in 2022, then grew by 12.28% to -$201.4 million in 2023, then dropped by 7.7% to -$216.9 million in 2024, then dropped by 14.48% to -$248.3 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$248.3 million in Q3 2025, -$247.7 million in Q2 2025, and -$357.3 million in Q1 2025.